Kobayashi Masao
Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences.
Rinsho Ketsueki. 2015 Oct;56(10):2230-9. doi: 10.11406/rinketsu.56.2230.
Neutrophil disorders are classified into abnormal neutrophil function and granulopoiesis. The identification of genetic defects causing neutropenia and neutrophil dysfunction has revealed the mechanisms controlling myeloid differentiation and their functions. The International Union of Immunological Societies of Primary Immunodeficiencies represents the most current catalog of approximately 30 neutrophil disorders. In this report, we show the progress made in studies of the pathophysiology and treatment of these disorders, focusing on chronic granulomatous disease (CGD) and severe congenital neutropenia (SCN). Hematopoietic stem cell transplantation (HSCT) is the only available curative therapy for CGD and SCN. However, the use of HSCT as treatment for both diseases is limited by transplant-related mortality (TRM) because of active infections and intractable inflammatory complications. Recently, reduced-intensity conditioning regimens have been introduced to minimize the TRM and the late adverse effects of HSCT for both diseases. The results of HSCT using the RIC regimen for 40 patients with CGD and SCN in Hiroshima University Hospital are summarized herein. Determining the optimal line of treatment will require further accumulation to cases to refine HSCT for both diseases.
中性粒细胞疾病分为中性粒细胞功能异常和粒细胞生成异常。对导致中性粒细胞减少和中性粒细胞功能障碍的基因缺陷的鉴定揭示了控制髓系分化及其功能的机制。国际免疫学会原发性免疫缺陷联盟列出了约30种中性粒细胞疾病的最新目录。在本报告中,我们展示了这些疾病在病理生理学和治疗研究方面取得的进展,重点关注慢性肉芽肿病(CGD)和严重先天性中性粒细胞减少症(SCN)。造血干细胞移植(HSCT)是目前唯一可治愈CGD和SCN的疗法。然而,由于活跃感染和难治性炎症并发症,HSCT作为这两种疾病的治疗方法受到移植相关死亡率(TRM)的限制。最近,已引入降低强度的预处理方案,以尽量减少这两种疾病的TRM和HSCT的晚期不良反应。本文总结了广岛大学医院对40例CGD和SCN患者使用RIC方案进行HSCT的结果。确定最佳治疗方案需要进一步积累病例,以完善这两种疾病的HSCT治疗。